Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3Pancreatic Intraductal Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 222Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × tocotrienol, delta × Clear all
NCT01450046 2016-07-07

Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01446952 2016-04-11

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00985777 2016-03-01

Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
26 enrolled
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡